Rockville cancer diagnostics company 20/20 Gene Systems Inc. recently completed a $4.5 million Series A equity funding round led by the venture capital division of China’s largest insurance company, Ping An Ventures.
CEO Jonathan Cohen told me the company seeks to grow its lung cancer detection test in the Asian market. The test, which measures a panel of tumor biomarkers, uses an algorithm that combines those biomarker values to generate a risk score.
